Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Indevus raises $60 million

IDEV raised $60 million through convertible senior notes which bear

Read the full 106 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE